"We will also look at those risk factors for cognitive decline that can be corrected, including stress, pain, vascular disease and poor sleep," says Richard B. Lipton, M.D., co-principal investigator on the grant and the Edwin S. Lowe Chair in Neurology at Einstein, professor and vice chair of neurology at Einstein and Montefiore. "By linking specific risk factors to cognitive decline in the study participants, we hope to develop personalized interventions that will prevent the onset of Alzheimer's dementia."
"Alzheimer's disease is usually diagnosed after many years of cognitive decline," says Martin J. Sliwinski, Ph.D., professor of human development and family studies at Penn State University, director of the Penn State Center for Healthy Aging and co-principal investigator on the grant. "The subtle changes in the brain and in cognition during pre-Alzheimer's are not well understood and can be difficult to track using typical one-time, in-person cognitive evaluations – 'snapshots' that can yield misleading results."
The researchers say accurate data from their study will provide insight into the natural progression of the disease, shed light on the variability between individuals and help evaluate treatment effectiveness.
The Einstein Aging Study will recruit 500 community dwelling participants over age 70 in the Bronx. The seniors will receive customized smartphones, which—over a 14-day period—will ask them multiple times a day to record their personal assessments on a range of measures and also play several short matching and memory games. These "measurement bursts" will allow the researchers to average multiple measurements so they can more accurately assess an individual's sense of well-being and cognitive status and track changes over time.
Participants will also wear fitness trackers to measure sleep patterns and activity, along with monitors to measure heart rate. Some will undergo magnetic resonance imaging (MRI) of their brains, allowing researchers to assess the hippocampus, the part of the brain associated with memory, and other cranial regions.
Dr. Lipton has led the Einstein Aging Study since 1992, focusing on the aging brain, normal aging, mild cognitive impairment, Alzheimer's disease and other dementing disorders. The study, supported since 1980 by grants from the National Institute on Aging, involves an interdisciplinary team of neurologists, neuropsychologists, neuropathologists, neurochemists, social workers and other health care professionals. Over the course of three decades, the study has supported pioneering research in cognitive aging, increased our understanding of preclinical states of dementia and served as a national and international resource for Alzheimer's disease research. The new NIH funding will allow investigators to expand their research scope by using this mobile phone-based approach and collaborating with experts at Penn State.
The grant is titled "Einstein Aging Study" (2P01AG003949-32). Additional researchers on the study include Mindy Katz, M.P.H., senior associate in the Saul R. Korey Department of Neurology, and Carol Derby, Ph.D., associate professor in the departments of neurology and epidemiology and population heath at Einstein, and Joshua Smyth, Ph.D., professor of biobehavioral health and medicine at Penn State, and Jacqueline Mogle, M.S., Ph.D., assistant professor in the College of Nursing at Penn State.
About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2016-2017 academic year, Einstein is home to 717 M.D. students, 166 Ph.D. students, 103 students in the combined M.D./Ph.D. program, and 278 postdoctoral research fellows. The College of Medicine has more than 1,900 full-time faculty members located on the main campus and at its clinical affiliates. In 2016, Einstein received more than $160 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.
Logo - http://photos.prnewswire.com/prnh/20120531/DC16559LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/einstein-and-penn-state-researchers-awarded-122-million-to-study-alzheimers-disease-300371403.html
SOURCE Albert Einstein College of Medicine